Form 4 for DNA Ginkgo Bioworks Holdings, Inc.

Accepted 2022-10-07 00:00:00 ET · period of report 2022-10-05 · accession 0000899243-22-033322 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-10-07	2022-10-05	DNA	Dmytruk Mark E.	See remarks	M - OptEx	—	+618.2K	627.3K	+6,792%	—
D	2022-10-07	2022-10-06	DNA	Dmytruk Mark E.	See remarks	S - Sale+OE	$3.25	-279.3K	348.1K	-45%	-$907.6K
D	2022-10-07	2022-10-05	DNA	Dmytruk Mark E.	See remarks	M - OptEx	—	-618.2K	39.9K	-94%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Class A Common Stock	2022-10-05	M	A	618,242	—	627,344	D	—	—	(F1) Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
2	Common	Class A Common Stock	2022-10-06	S	D	279,255	$3.25	348,089	D	—	—
3	Derivative	Class B Common Stock	2022-10-05	M	D	618,242	—	39,891	D	— · — to —	— Class A Common Stock	(F3) Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. (F4) Excludes restricted stock units, which were previously reported as shares of Class B common stock on the Form 4 filed by the reporting person on March 14, 2022. Because the Issuer has the ability to settle such restricted stock units with shares of Class A common stock or cash upon vesting, restricted stock units will be reported separately from shares of Class B Common Stock in future reports.